

Serogroup B Meningococcal (MenB) ®

Age Indications for MenB® Vaccine

MenB®: for aged 10 years through 25 years of age who are at increased risk for meningococcal disease

MenB Vaccines:

- Bexsero®: for persons aged 10 years through 25 years; 2 dose series (0.5mL each) at least 1 month apart
- Trumenba® : for persons aged 10 years through 25 years; 3 dose series (0.5mL each) at 0-, 2-, and 6- month schedule
- The same vaccine must be used for all doses
- These vaccines may also be given to anyone 16 through 23 years old to provide short term protection against most strains of serogroup B meningococcal disease; 16 through 18 years are the preferred ages for vaccination

Indications for Use and Schedule


- Indicated to prevent meningococcal disease caused by serogroup B. Other meningococcal vaccines are recommended to help protect against serogroups A, C, W, and Y.

Vaccine Administration

- Intramuscular (IM) injection in the deltoid muscle of the arm
 - 1-1.5 inch, 22-25 gauge needle
- Use professional judgment in selecting needle length

Storage and Handling

- Store in the refrigerator between 35°-46° F (2°-8° C); Do NOT freeze
- Protect vials from light.
- Keep in the original box
- Administer vaccine immediately after drawn up in syringe



Routine Recommendation for people 10 years or older who are at risk for serogroup B meningococcal infections:

- People at risk because of a serogroup B meningococcal disease outbreak
- Anyone whose spleen is damaged or has been removed
- Anyone with a rare immune system condition called "persistent complement component deficiency"
- Anyone taking a drug called eculizumab (also called Soliris®)
- Microbiologists who routinely work with *N. meningitidis* isolates

Contraindications

- An anaphylactic (severe allergic) reaction to a prior dose, any component of serogroup B meningococcal vaccine, or any severe allergy to latex

Precautions

- If you are pregnant or breastfeeding; it should be used during pregnancy only if clearly needed
- If you are not feeling well; it is usually okay to get this vaccine when you have a mild illness, but you might be advised to come back when you feel better

Further Points

- More than half of the people who get serogroup B meningococcal vaccine have mild problems following vaccination. These reactions can last up to 3 to 7 days, and include (soreness, redness, or swelling at administration site, tiredness or fatigue, headache, muscle or joint pain, fever or chills, nausea or diarrhea)
- People sometimes faint after a medical procedure, including vaccination. Sitting or lying down for about 15 minutes can help prevent fainting, and injuries caused by a fall
- MenB may be administered concomitantly with other vaccines indicated for this age, but at a different anatomic site, if feasible
- Even though both MenB vaccines are FDA-licensed for people 10 through 25 years of age, ACIP recommends the vaccines can be used off-label for those at increased risk of serogroup B meningococcal disease who are 26 years of age or older. In contrast to (MCV4 [MenACWY]) recommendations, MenB vaccine is not routinely recommended for college students or international travelers
- Q&As regarding the use of both MCV4 and MenB in adolescents are available on the CDC website at www.cdc.gov/vaccines/vpd-vac/mening/faqs-hcp-adolescent-vaccine.html
- Serogroup B Meningococcal Vaccine Information Statement (VIS), can be found at <http://www.immunize.org/vis/>
- The new MenB recommendations are classified as Category B, meaning the recommendations allow for individual clinical decision making; Category B classification enables coverage by the Vaccines For Children program and most insurance plans

Resources:

"Use of Serogroup B Meningococcal Vaccine in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015," available at www.cdc.gov/mmwr/pdf/wk/mm6441.pdf, pages 1171-6.